Cargando…

Bedside Intestinal Ultrasound Performed in an Inflammatory Bowel Disease Urgent Assessment Clinic Improves Clinical Decision-Making and Resource Utilization

BACKGROUND: Patients with inflammatory bowel disease (IBD) require accessible, timely, and noninvasive strategies to monitor disease. The aim was to assess the integration of intestinal ultrasound (IUS) on decision-making and endoscopy utilization in a standardized care pathway. METHODS: This prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: St-Pierre, Joëlle, Delisle, Maxime, Kheirkhahrahimabadi, Hengameh, Goodsall, Thomas M, Bryant, Robert V, Christensen, Britt, Vaughan, Rose, Al-Ani, Aysha, Ingram, Richard J M, Heatherington, Joan, Carter, Dan, Lu, Cathy, Ma, Christopher, Novak, Kerri L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558199/
https://www.ncbi.nlm.nih.gov/pubmed/37809033
http://dx.doi.org/10.1093/crocol/otad050
Descripción
Sumario:BACKGROUND: Patients with inflammatory bowel disease (IBD) require accessible, timely, and noninvasive strategies to monitor disease. The aim was to assess the integration of intestinal ultrasound (IUS) on decision-making and endoscopy utilization in a standardized care pathway. METHODS: This prospective, multicenter, international, observational cohort study included patients seen within a centralized model for IBD care was conducted during the COVID pandemic. Patients were evaluated with IUS alone or in combination with an in-clinic, unsedated sigmoidoscopy. Demographic, clinical, laboratory, and imaging data, clinical decisions, and need for urgent endoscopy, hospitalization, and surgeries were recorded. RESULTS: Of the 158 patients included, the majority had an established diagnosis of Crohn’s disease (n = 123, 78%), and 47% (n = 75) of patients were on biologic therapy. IUS identified active inflammation in 65% (n = 102) of patients, and strictures in 14% (n = 22). Fecal calprotectin levels correlated with inflammation detected on IUS (median of 50 μg/g [Q1–Q3: 26–107 μg/g] without inflammation and 270 μg/g [Q1–Q3: 61–556 μg/g] with inflammation; p = 0.0271). In the majority of patients, clinical assessment with IUS led to an acute change in IBD-specific medications (57%, n = 90) and avoided or delayed the need for urgent endoscopy (85%, n = 134). Four patients were referred for urgent surgical consultation. CONCLUSIONS: Point-of-care IUS used in a flare clinic pathway is a useful strategy to improve effective IBD care delivery and to assist in therapeutic management decisions, in many cases avoiding the acute need for endoscopy.